Industry Focus Transcripts

Energy storage is a hot topic these days. Here's who is currently leading the charge.

Carl Icahn's reportedly focusing his brand of investor activism on Bristol-Myers Squibb, but it's anyone's guess if he'll be able to convince the company to sell. Also, Celgene delivers a phase 3 win with blockbuster implications.

Fool.com contributor Daniel Kline offers his take on major trends currently driving innovation and growth at your favorite quick service restaurants.

Snap is one of the hottest potential IPOs of 2017. Now that we've had a chance to look at the numbers, should investors keep it on their watch list once shares start trading?

Hear the story behind this "unicorn" company.

In this Valentine's Day edition, Industry Focus explores cholesterol busters, heart surgery, and the latest in anticoagulants.

BP plc has released its 2017 Energy Outlook that extends to 2035. For long-term investors, BP's opinions may be both surprising and thought-provoking.

There are many green stocks in the marketplace. Here are two of the top plays today.

If you’re interested in learning more about the Dodd-Frank Act of 2010, then this is the podcast episode for you.

We explain why Facebook and Shopify are two tech stocks we really like and answer Gaby Lapera's questions about the companies.

We're breaking down quarterly results from two Fool favorites, Alphabet and PayPal. We hit the headline numbers, key metrics, and dig through management's comments to catch all the info investors need to know.

Apple's recent quarterly check-ins have been fairly ho-hum, but not this time! The Mac maker is back to growth after an impressive quarter.

We’re pitting off gene sequencing giant Illumina against giant biotech Gilead Sciences to see which company is the better buy for long-term investors.

Two great stocks in the financials sector face off against each other.

A look at what parts of the world use what renewable energy and how much they use, and how bright the future looks for the green-energy industry.

We welcome financials analyst Gaby Lapera to the show to share some of our favorite stocks in the consumer and retail sector. In this case, we have two leading companies in their respective industries that can still make for a David and Goliath story.

Will Airbnb launch its IPO in 2017? Is Macau officially on track for a recovery? Will Japan eventually become the new casino capital of the world? Fool.com contributor Seth McNew shares his insights after traveling through the region.

Competitors make headway against Teva Pharmaceutical's top seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know.

Aircraft production is basically a duopoloy with just two major players -- here’s what investors need to know.

From a big-time patent settlement between Merck & Co. and Bristol-Myers Squibb, to Johnson & Johnson's earnings, to Aetna and Humana's $37 billion merger bust, we dive into the details behind last week's biggest healthcare stories.